Zolmitriptan
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (S)-4-({3-[2-(dimetilamino)etil]-1H-indol-5-il}metil)-1,3-oksazolidin-2-on | |||
| Klinički podaci | |||
| Robne marke | Zomig | ||
| AHFS/Drugs.com | Monografija | ||
| Identifikatori | |||
| CAS broj | 139264-17-8 | ||
| ATC kod | N02CC03 | ||
| PubChem[1][2] | 60857 | ||
| DrugBank | DB00315 | ||
| ChemSpider[3] | 54844 | ||
| UNII | 2FS66TH3YW 
| ||
| KEGG[4] | D00415
| ||
| ChEBI | CHEBI:10124
| ||
| ChEMBL[5] | CHEMBL1185
| ||
| Hemijski podaci | |||
| Formula | C16H21N3O2 | ||
| Mol. masa | 287,357 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakokinetički podaci | |||
| Bioraspoloživost | 40% (oralno) | ||
| Vezivanje za proteine plazme | 25% | ||
| Metabolizam | Hepatički (CYP1A2 posredovano, do aktivnog metabolita) | ||
| Poluvreme eliminacije | 3 sata | ||
| Izlučivanje | Renalno (65%) i fekalno (35%) | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | B3(AU) C(US) | ||
| Pravni status | ℞-only (SAD) | ||
| Način primene | Oralno, nazalni sprej | ||
Zolmitriptan (Zomig, Zomigon, AscoTop, Zomigoro) je selektivan agonist serotoninskog receptora, 1B i 1D podtipova. On je triptan koji se koristi za tretman napada akutne migrene.[6][7]
Reference[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- ↑ Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0.
Literatura[uredi | uredi kod]
- MacGregor, E.A. (1998). „Zolmitriptan clinical studies”. Drugs Today 34 (12): 1027-1033. DOI:10.1358/dot.1998.34.12.487488. PMID 14743270.
